Metropolitan Life Insurance Co. NY Reduces Stake in Bio-Rad Laboratories, Inc. (BIO)

Metropolitan Life Insurance Co. NY decreased its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 0.1% during the first quarter, according to its most recent filing with the SEC. The fund owned 19,376 shares of the medical research company’s stock after selling 19 shares during the period. Metropolitan Life Insurance Co. NY owned about 0.07% of Bio-Rad Laboratories worth $3,862,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. Advisory Services Network LLC bought a new stake in Bio-Rad Laboratories during the first quarter worth $115,000. Flinton Capital Management LLC boosted its stake in Bio-Rad Laboratories by 17.6% in the first quarter. Flinton Capital Management LLC now owns 640 shares of the medical research company’s stock worth $128,000 after buying an additional 96 shares during the last quarter. Meadow Creek Investment Management LLC boosted its stake in Bio-Rad Laboratories by 17.6% in the first quarter. Meadow Creek Investment Management LLC now owns 880 shares of the medical research company’s stock worth $175,000 after buying an additional 132 shares during the last quarter. Dowling & Yahnke LLC bought a new stake in Bio-Rad Laboratories during the first quarter worth $201,000. Finally, World Asset Management Inc bought a new stake in Bio-Rad Laboratories during the first quarter worth $202,000. 63.85% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Bio-Rad Laboratories, Inc. (NYSE BIO) opened at 225.79 on Wednesday. The company has a 50 day moving average of $222.92 and a 200 day moving average of $202.79. The company has a market cap of $6.68 billion, a PE ratio of 239.69 and a beta of 0.91. Bio-Rad Laboratories, Inc. has a 52 week low of $142.06 and a 52 week high of $233.51.

Bio-Rad Laboratories (NYSE:BIO) last released its earnings results on Thursday, May 4th. The medical research company reported $0.41 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.27 by $0.14. Bio-Rad Laboratories had a net margin of 1.35% and a return on equity of 3.23%. The company had revenue of $500.05 million for the quarter, compared to analyst estimates of $477.76 million. During the same quarter last year, the firm earned $0.42 EPS. The firm’s quarterly revenue was up 6.1% compared to the same quarter last year. On average, analysts expect that Bio-Rad Laboratories, Inc. will post $2.85 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This story was first reported by BBNS and is the sole property of of BBNS. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://baseballnewssource.com/markets/metropolitan-life-insurance-co-ny-reduces-stake-in-bio-rad-laboratories-inc-bio/1180112.html.

A number of research firms have weighed in on BIO. Zacks Investment Research cut shares of Bio-Rad Laboratories from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 5th. BidaskClub cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, June 14th. Jefferies Group LLC reaffirmed a “buy” rating and set a $250.00 target price on shares of Bio-Rad Laboratories in a research note on Thursday, April 27th. Finally, Deutsche Bank AG raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and decreased their target price for the stock from $220.00 to $195.00 in a research note on Wednesday, June 28th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $217.25.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Todd Frazier Traded to Yankees for Blake Rutherford and Others
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Todd Frazier Trade to Boston Appears to Be Decided
Todd Frazier Trade to Boston Appears to Be Decided
Chicago White Sox Continue Rebuild Without Jose Quintana
Chicago White Sox Continue Rebuild Without Jose Quintana
Mike Trout Returns from Injury With Single and Stole Base
Mike Trout Returns from Injury With Single and Stole Base
Chicago Cubs Strengthen Rotation Through Trade for Jose Quintana
Chicago Cubs Strengthen Rotation Through Trade for Jose Quintana


Leave a Reply

 
© 2006-2017 BBNS.